CCIA
MCRB icon

Campbell & Co Investment Adviser’s Seres Therapeutics MCRB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-390
Closed -$221K – 514
2020
Q3 		$221K Buy
+390
New +$130K 0.16% 283

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Campbell & Co Investment Adviser's MCRB Position: Q4 2020 in Review

Campbell & Co Investment Adviser sold out of Seres Therapeutics (MCRB) in Q4 2020, closing a stake of 390 shares — an estimated $221K sold.

Campbell & Co Investment Adviser first reported a position in MCRB in Q3 2020 and held it in 1 quarter. The position peaked at $221K in Q3 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q4 2020.

  • Campbell & Co Investment Adviser reported no remaining Seres Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 390 Seres Therapeutics shares in Q4 2020, an estimated $221K.
  • Campbell & Co Investment Adviser first reported a position in Seres Therapeutics in Q3 2020 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Seres Therapeutics position peaked at $221K in Q3 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2020, filed 9 Feb 2021.